Arsanis Inc (NASDAQ:ASNS) shot up 9.8% on Monday . The company traded as high as $2.74 and last traded at $2.02. 4,600 shares changed hands during trading, a decline of 96% from the average session volume of 114,169 shares. The stock had previously closed at $1.84.
A number of brokerages recently weighed in on ASNS. Piper Jaffray Companies dropped their price objective on Arsanis to $2.50 and set a “neutral” rating on the stock in a research report on Monday, August 13th. Citigroup downgraded Arsanis from a “buy” rating to a “neutral” rating in a research report on Monday, July 9th. Cowen downgraded Arsanis from an “outperform” rating to a “market perform” rating in a report on Monday, July 2nd. Cantor Fitzgerald reissued a “buy” rating and issued a $26.00 price target on shares of Arsanis in a report on Thursday, June 28th. Finally, Zacks Investment Research raised Arsanis from a “hold” rating to a “buy” rating and set a $4.00 price target for the company in a report on Tuesday, July 10th. Four research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $14.88.
The company has a debt-to-equity ratio of 0.20, a current ratio of 5.54 and a quick ratio of 5.54. The firm has a market capitalization of $23.19 million and a price-to-earnings ratio of -0.13.
Arsanis (NASDAQ:ASNS) last issued its quarterly earnings results on Monday, August 13th. The company reported ($0.85) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($0.03). Research analysts anticipate that Arsanis Inc will post -3.12 earnings per share for the current fiscal year.
A number of hedge funds and other institutional investors have recently modified their holdings of ASNS. Schwab Charles Investment Management Inc. acquired a new stake in Arsanis in the first quarter worth about $200,000. Northern Trust Corp acquired a new stake in Arsanis in the first quarter worth about $735,000. BlackRock Inc. acquired a new stake in Arsanis in the first quarter worth about $4,029,000. JPMorgan Chase & Co. boosted its holdings in Arsanis by 6.4% in the first quarter. JPMorgan Chase & Co. now owns 247,415 shares of the company’s stock worth $5,663,000 after acquiring an additional 14,819 shares in the last quarter. Finally, New York State Common Retirement Fund acquired a new stake in Arsanis in the first quarter worth about $114,000. 68.70% of the stock is owned by institutional investors and hedge funds.
Arsanis Company Profile (NASDAQ:ASNS)
Arsanis, Inc, a clinical-stage biopharmaceutical company, focuses on applying monoclonal antibody (mAb) immunotherapies to address infectious diseases. Its lead product candidate is ASN100, a mAb therapeutic in Phase II clinical development for the prevention of staphylococcus aureus pneumonia in mechanically ventilated patients.
Recommended Story: Price to Earnings Ratio (PE) Basics
Receive News & Ratings for Arsanis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arsanis and related companies with MarketBeat.com's FREE daily email newsletter.